Monday, January 05, 2015 10:11:35 PM
"There are a few things that you need to know about the market maker NITE. Knight Securities uses the ticker $NITE. This market maker is known for being one of the most abusive market makers in the penny stock market. Most of the popular penny stock brokers route from NITE because they are quick to execute most orders. One thing that I’ve noticed is that NITE tries to screw you over. You have to realize that each market maker has it’s own complex algorithm that tries to make them money. Sometimes they make money by shorting the ask and then covering on the bid. Sometimes when a stock is running and you place an order on the ask and you don’t get filled, it is actually the market maker taking shares on the ask. Then they move up the bid and ask and tries to bait traders into hitting the ask again to sell the shares that they just bought. You’ll also see MM’s shorting a stock as it runs up because they know that it will eventually come down. Think of it this way. If they are able to short a stock at .01 and it runs to .10, you will hear people on the stock forums saying, shorty is going to get burned, or this market maker is short. In reality, it really won’t matter because naked shorting really isn’t enforced and any short will eventually be able to cover if they just keeping shorting more. If they short at .01, .02, .03…to .10 it appears that they are really short.
Then what happens is they keep shorting more at the top say at around .10. Then the promotion is over and then over the next few days the MM is able to short more in the .06 to .08 range. People keep buying because they think more is coming, but the promo is over. The price keeps decreasing over the next month back to .02 to .03 range where the MM is able to cover for a profit. So as you can see the market makers like NITE never lose and it is only the bag holders."
http://www.penny-stock-brokers.org/mm-nite-shorting/
Recent AEMD News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2024 10:15:18 PM
- Aethlon Medical Announces Financial Results for the Fiscal Second Quarter Ended September 30, 2024 and Provides Corporate Update • PR Newswire (US) • 11/13/2024 09:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/12/2024 02:00:08 PM
- Aethlon Medical Reaches Key Milestone with Enrollment of the First Patient in (FPI) Its Hemopurifier® Cancer Trial in Australia • PR Newswire (US) • 11/11/2024 01:01:00 PM
- Aethlon Medical to Release Fiscal Second Quarter Financial Results and Host Conference Call on November 13, 2024 • PR Newswire (US) • 11/06/2024 01:01:00 PM
- Aethlon Medical to Participate in the 2024 Maxim Healthcare Virtual Summit • PR Newswire (US) • 10/08/2024 12:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/03/2024 08:44:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/02/2024 09:00:09 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/01/2024 09:30:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/01/2024 09:30:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/01/2024 09:30:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/19/2024 12:01:08 PM
- Aethlon Receives Ethics Committee Approval for Hemopurifier® Cancer Trial in India • PR Newswire (US) • 09/19/2024 12:01:00 PM
- Aethlon Medical Announces Activation of Royal Adelaide Hospital to Begin Patient Screening and Enrollment in Hemopurifier® Cancer Trial • PR Newswire (US) • 09/16/2024 12:01:00 PM
- Aethlon Medical to Present at the Life Sciences Investor Forum September 19th • GlobeNewswire Inc. • 09/13/2024 12:35:00 PM
- Aethlon Medical Announces Publication of Preclinical Data Showing Ability of the Hemopurifier® to Remove Extracellular Vesicles and microRNAs from Renal Perfusates Following Controlled Oxygenated Rewarming of Discarded Donor Kidneys • PR Newswire (US) • 08/27/2024 12:01:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 08/15/2024 08:34:03 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 08/15/2024 08:32:05 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 08/15/2024 08:30:33 PM
- Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend] • Edgar (US Regulatory) • 08/15/2024 08:15:29 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2024 09:10:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2024 08:15:21 PM
- Aethlon Medical Announces Financial Results for the Fiscal First Quarter Ended June 30, 2024 and Provides Corporate Update • PR Newswire (US) • 08/14/2024 08:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/12/2024 12:01:08 PM
- Aethlon Medical Receives Second Ethics Committee Approval for Hemopurifier® Cancer Trial • PR Newswire (US) • 08/12/2024 12:01:00 PM
Alliance Creative Group (ACGX) Releases Q3 2024 Financial and Disclosure Report with an increase of over 100% in Net Income for 1st 9 months of 2024 vs 2023 • ACGX • Nov 14, 2024 8:30 AM
Unitronix Corp. Publishes Its Cryptocurrency Portfolio Strategy • UTRX • Nov 14, 2024 8:05 AM
Avant Technologies and Ainnova Tech Form Joint Venture to Advance Early Disease Detection Using Artificial Intelligence • AVAI • Nov 12, 2024 9:00 AM
Swifty Global Announces Launch of Swifty Sports IE, Expanding Sports Betting and Casino Services in the Irish Market • DRCR • Nov 12, 2024 9:00 AM
Oohvie App Update Enhances Women's Health with Telemedicine and Online Scheduling • HLYK • Nov 11, 2024 8:00 AM
SANUWAVE Announces Record Quarterly Revenues: Q3 FY2024 Financial Results • SNWV • Nov 8, 2024 7:07 AM